NasdaqGS:NTRABiotechs
Natera (NTRA) On Prospera Coverage Expansion And Revenue Strength Looks Fully Valued
Natera (NTRA) stock is in focus after two key developments: a final local coverage determination expanding Prospera transplant test access and stronger than expected revenue growth supported by higher testing volumes.
See our latest analysis for Natera.
Natera’s recent developments appear to be reflected in its share price, with a 30.2% 90 day share price return and a very large 3 year total shareholder return that suggests momentum has been building over a longer period.
If Natera’s move has...